H. Lundbeck Overview
- Year Founded
-
1915
- Status
-
Public
- Employees
-
5,000
- Stock Symbol
-
HLUN A
- Investments
-
29
- Share Price
-
$8.60
- (As of Friday Closing)
H. Lundbeck General Information
Description
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Contact Information
Website
www.lundbeck.comCorporate Office
- Ottiliavej 9
- Valby
- 2500 Copenhagen
- Denmark
Corporate Office
- Ottiliavej 9
- Valby
- 2500 Copenhagen
- Denmark
H. Lundbeck Stock Performance
As of 13-Nov-2026, H. Lundbeck’s stock price is $8.60. Its current market cap is $8.67B with 992M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.60 | $8.44 | $4.86 - $9.20 | $8.67B | 992M | 129K | $0.65 |
H. Lundbeck Financials Summary
As of 30-Sep-2026, H. Lundbeck has a trailing 12-month revenue of $4.09B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,618,413 | 7,929,728 | 4,932,998 | 4,694,273 |
| Revenue | 4,086,710 | 3,721,235 | 3,191,793 | 2,889,583 |
| EBITDA | 841,317 | 1,007,287 | 796,353 | 721,670 |
| Net Income | 641,211 | 482,265 | 455,908 | 332,319 |
| Total Assets | 8,168,284 | 8,186,007 | 8,044,534 | 5,553,889 |
| Total Debt | 1,313,418 | 1,832,707 | 2,328,953 | 616,307 |
H. Lundbeck Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
H. Lundbeck Comparisons
Industry
Financing
Details
H. Lundbeck Competitors (50)
One of H. Lundbeck’s 50 competitors is Novo Nordisk, a Corporation company based in Bagsvaerd, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Chiesi Farmaceutici | Private Debt Financed | Parma, Italy |
H. Lundbeck Patents
H. Lundbeck Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026190230-A1 | Alpha-synuclein antibodies for use in diagnostic assays and treatment of alpha-synucleinopathies | Pending | 13-Mar-2025 | ||
| WO-2026120069-A1 | Humanized anti-pacap antibody and uses thereof | Pending | 05-Dec-2024 | ||
| WO-2026114911-A1 | Orexin 2 receptor agonists | Pending | 27-Nov-2024 | ||
| WO-2026114912-A1 | Orexin 2 receptor agonists | Pending | 27-Nov-2024 | ||
| US-20260144795-A1 | Spiromacrocyclic orexin 2 receptor agonists | Pending | 27-Nov-2024 | A61K31/529 |
H. Lundbeck Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
H. Lundbeck Investments & Acquisitions (29)
H. Lundbeck’s most recent deal was a Accelerator/Incubator with Saventic Health. The deal was made on 05-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Saventic Health | 05-Mar-2025 | Accelerator/Incubator | Diagnostic Equipment | ||
| Longboard Pharmaceuticals | 02-Dec-2024 | Merger/Acquisition | Drug Discovery | ||
| AprilBio (Lu AG22515) | 01-Oct-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Alder Biopharmaceuticals | 22-Oct-2019 | Merger/Acquisition | Drug Discovery | ||
| Abide Therapeutics | 29-May-2019 | Merger/Acquisition | Drug Discovery |
H. Lundbeck ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
H. Lundbeck Exits (14)
H. Lundbeck’s most recent exit was on 19-Apr-2018 from BenevolentAI. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| BenevolentAI | 19-Apr-2018 | Completed |
|
||
| Aptinyx | 15-Sep-2015 | Completed |
|
||
| BenevolentAI | 01-Aug-2015 | Completed |
|
||
| Naurex | 02-Dec-2014 | Completed |
|
||
| BenevolentAI | 17-Oct-2014 | PE Growth/Expansion | Completed |
|
H. Lundbeck Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Longboard Pharmaceuticals | La Jolla, CA | 2020 | |
| Lundbeck Business Service Center | Krakow, Poland | 2014 | |
| Lundbeck Export | Valby, Denmark | 2001 | |
| Lundbeck Poland | Warsaw, Poland | 1997 | |
| Lundbeck | Puteaux, France | 1984 |
H. Lundbeck FAQs
-
When was H. Lundbeck founded?
H. Lundbeck was founded in 1915.
-
Where is H. Lundbeck headquartered?
H. Lundbeck is headquartered in Copenhagen, Denmark.
-
What is the size of H. Lundbeck?
H. Lundbeck has 5,000 total employees.
-
What industry is H. Lundbeck in?
H. Lundbeck’s primary industry is Pharmaceuticals.
-
Is H. Lundbeck a private or public company?
H. Lundbeck is a Public company.
-
What is H. Lundbeck’s stock symbol?
The ticker symbol for H. Lundbeck is HLUN A.
-
What is the current stock price of H. Lundbeck?
As of 13-Nov-2026 the stock price of H. Lundbeck is $8.60.
-
What is the current market cap of H. Lundbeck?
The current market capitalization of H. Lundbeck is $8.67B.
-
What is H. Lundbeck’s current revenue?
The trailing twelve month revenue for H. Lundbeck is $4.09B.
-
Who are H. Lundbeck’s competitors?
Novo Nordisk, Astellas Pharma, Johnson&Johnson Innovative Medicine, Merck & Co., and Chiesi Farmaceutici are some of the 50 competitors of H. Lundbeck.
-
What is H. Lundbeck’s annual earnings per share (EPS)?
H. Lundbeck’s EPS for 12 months was $0.65.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
